🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

TIP Moonrise1. TAR210🥨 Roger Li great job. #aua2025 Fgfr3 targeting half way enrolled.

For US #HCPs at #AUA25: don't miss Dr. Roger Li (Roger Li) share learnings from the Phase 3 MoonRISe-1 study in patients with FGFR-altered intermediate-risk non–muscle-invasive #BladderCancer. clinicaltrials.gov/study/NCT06319…

Live from the AUA-IBCG Bladder Forum - Follow this thread for takeaways from each debate on current controversies in bladder cancer. Ashish M. Kamat, MD, MBBS is kicking off an afternoon of debates between global experts covering key issues in bladder cancer. #AUA25 IBCG

Debate 7. Should ctDNA guide adjuvant treatment decisions post-RC? #AUA25 Petros Grivas Matt Galsky Roger Li Yes! Move to precision medicine, reduce potential for substantial toxicities. Jonathan Rosenberg MD Not yet! No prospective phase 3 trial data. Over 30% of patients who

And … we did it! Thanks to everyone who showed up – not just to engage with the latest and cutting-edge debates in bladder cancer, but most importantly, to stand in support of our patients. AUA-IBCG Bladder Cancer Forum #AUA25 Amer. Urol. Assn. IBCG Kelly Bree

#MoonRISe-1: Phase 3 study of TAR-210, an intravesical erdafitinib releasing system, vs intravesical chemotherapy in patients with FGFR-altered intermediate-risk #NMIBC. Presented by Roger Li Moffitt Cancer Center. #AUA25 written coverage by Rashid K. Sayyid USC > bit.ly/4iHIKLt

Another high-level, educational, multi-disciplinary IBCG #AUA25 Forum! 4th annual at Amer. Urol. Assn. Congrats to Ashish M. Kamat, MD, MBBS Kelly Bree Taeweon Lee Coverage of all 8 debates on UroToday.com urotoday.com/conference-hig…

#AUA25 Debate Spotlight: Should ctDNA guide adjuvant therapy after radical cystectomy? Roger Li & Jonathan Rosenberg MD face off at the #IBCGBladderCancerForum—precision medicine vs. current evidence. Post-debate shift: 🗳️ "Yes": 54% ➡️ 46% 🗳️ "Not yet": 46% ➡️ 54% Written coverage

While at #AACR25, I had a great discussion with Dr. John Cleveland, Center Director and Chief Scientific Officer Moffitt Cancer Center, about some of the most exciting findings coming out of the conference. AACR #MoffittAACR25

Excited to see our paper in print European Urology: europeanurology.com/article/S0302-… Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma

Honored to be recognized by the SUO with this prestigious award. Humbled to be amongst my esteemed predecessors. Much more to do in #bladdercancer Society of Urologic Oncology Amer. Urol. Assn. Bladder Cancer Advocacy Network IBCG Moffitt Urologic Oncology Fellowship Moffitt Cancer Center

POTOMAC trial- Durvalumab + BCG shows positive results for DFS in high-risk NMIBC vs BCG alone. sasanlimab (CREST) also had an EFS advantage here: HR 0.68. Consistent results in early disease is compelling. IO tox is relevant in risk/benefit ratio. astrazeneca.com/media-centre/p…

We tested the feasibility and immunogenicity of a personalized neoantigen vaccine + PD-L1 blockade in #bladdercancer including the adjuvant setting. nature.com/articles/s4301… Jon Anker, MD, PhD Bhardwaj Lab UroToday.com Uromigos The Tisch Cancer Institute Dr. Bishoy M. Faltas Nature Cancer Bladder Cancer Advocacy Network

Just in case anyone missed this? prnewswire.com/news-releases/… UroToday.com Uromigos Bladder Cancer Advocacy Network

💡The best systematic reviews bring together a host of treatments in one paper for an easy reference 👏Saum Ghodoussipour et al. do that for #NMIBC strategies European Urology 🔗shorturl.at/iKtml Roger Li Sarah P. Psutka MD MS Mark Tyson Bladder Cancer Advocacy Network Gianluca Giannarini

Review – Bladder Cancer: The Financial Burden of Localized and Metastatic Bladder Cancer by Pietro Scilipoti, Marco Moschini et al Read the full article here: buff.ly/44pcBYA #UroSoMe #MedTwitter #EurUrol #BladderCancer

Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism" —the 1st human to undergo custom genome editing —outgrowth of decades of NIH funded research nejm.org/doi/full/10.10… nejm.org/doi/full/10.10… NEJM

FDA’s ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC onclive.com/view/fda-s-oda…

Update letter from Merck on TICE BCG timed for #ASCO25 “We are on track to complete the project on time and expect our plant to open by late 2026 ... facility is expected to triple our TICE BCG manufacturing capacity … meet the needs of physicians and patients for the

From #ASCO25: Roger Li, MD (Roger Li), shares insights on the latest bladder cancer research presented at ASCO and its potential impact on patient care. #MoffittASCO25